Alnylam Pharmaceuticals reported preliminary fourth quarter 2024 revenues of approximately $451 million and full year revenues of about $1,646 million, along with guidance for 2025 product revenues and operating income.
AI Assistant
ALNYLAM PHARMACEUTICALS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.